{"title":"长春地辛治疗抗melphalan多发性骨髓瘤","authors":"B. Houwen, Th. Ockhuizen, J. Marrink, H.O. Nieweg","doi":"10.1016/0014-2964(81)90040-2","DOIUrl":null,"url":null,"abstract":"<div><p>Vindesine, a new vinca alkaloid, was administered in thirteen patients with advanced multiple myeloma (stages <em>IIIA</em> and <em>IIIB</em>), resistant to alkylating agents. Eleven patients received two complete courses and could be evaluated. Six patients (<em>55%</em>) showed objective improvement. This was indicated by a decrease of greater than <em>50%</em> of pretreatment myeloma protein serum levels, normalization of elevated serum calcium levels, and improvement of haemoglobin concentration and renal function. Neutropenia of short duration, mild paraesthesias and alopecia were noted as side effects.</p></div>","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 2","pages":"Pages 227-232"},"PeriodicalIF":0.0000,"publicationDate":"1981-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90040-2","citationCount":"19","resultStr":"{\"title\":\"Vindesine therapy in melphalan-resistant multiple myeloma\",\"authors\":\"B. Houwen, Th. Ockhuizen, J. Marrink, H.O. Nieweg\",\"doi\":\"10.1016/0014-2964(81)90040-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Vindesine, a new vinca alkaloid, was administered in thirteen patients with advanced multiple myeloma (stages <em>IIIA</em> and <em>IIIB</em>), resistant to alkylating agents. Eleven patients received two complete courses and could be evaluated. Six patients (<em>55%</em>) showed objective improvement. This was indicated by a decrease of greater than <em>50%</em> of pretreatment myeloma protein serum levels, normalization of elevated serum calcium levels, and improvement of haemoglobin concentration and renal function. Neutropenia of short duration, mild paraesthesias and alopecia were noted as side effects.</p></div>\",\"PeriodicalId\":100497,\"journal\":{\"name\":\"European Journal of Cancer (1965)\",\"volume\":\"17 2\",\"pages\":\"Pages 227-232\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1981-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/0014-2964(81)90040-2\",\"citationCount\":\"19\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Cancer (1965)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/0014296481900402\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer (1965)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/0014296481900402","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Vindesine therapy in melphalan-resistant multiple myeloma
Vindesine, a new vinca alkaloid, was administered in thirteen patients with advanced multiple myeloma (stages IIIA and IIIB), resistant to alkylating agents. Eleven patients received two complete courses and could be evaluated. Six patients (55%) showed objective improvement. This was indicated by a decrease of greater than 50% of pretreatment myeloma protein serum levels, normalization of elevated serum calcium levels, and improvement of haemoglobin concentration and renal function. Neutropenia of short duration, mild paraesthesias and alopecia were noted as side effects.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
